Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 23, 2022 - Issue 18
Submit an article Journal homepage
208
Views
2
CrossRef citations to date
0
Altmetric
Drug Evaluation

Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China

Danling Gua Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing, Jiangsu, China;b Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu, ChinaORCID Iconhttps://orcid.org/0000-0001-8555-9900View further author information
ORCID Icon,
Jianyong Lia Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing, Jiangsu, China;b Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu, ChinaCorrespondence[email protected]
View further author information
&
Yi Miaoa Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing, Jiangsu, China;b Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China;c Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu, ChinaCorrespondence[email protected]
View further author information
Pages 1979-1986 | Received 14 Jun 2022, Accepted 31 Oct 2022, Published online: 11 Nov 2022

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Paweł Robak, Magda Witkowska, Anna Wolska-Washer & Tadeusz Robak. (2023) The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies. Expert Opinion on Drug Discovery 18:10, pages 1065-1076.
Read now

Articles from other publishers (1)

Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Anna Krupa & Dariusz Pawlak. (2023) Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. Molecules 28:5, pages 2400.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.